Supplementary Data FS3 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV⁺ Men

Supplementary Figure S3: Type of T cells responding to HPV16 oncoproteins.</p

Supplementary Data FS2 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV⁺ Men

Supplementary Figure S2: HPV16-specific T cell responses at different dose levels and time points.</p

Supplementary Data FS1 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV⁺ Men

Supplementary Figure S1: Trial Flowchart.</p

Supplementary Data TS2 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV⁺ Men

Supplementary Table S2: T-cell responses determined by 4-day IFNγ-ELISPOT assay.</p

Supplementary Data TS3 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV⁺ Men

Supplementary Table S3: Representativeness of Study Participants.</p

Supplementary Data TS1 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV⁺ Men

Supplementary Table S1: Proliferative T-cell responses determined by Lymphocyte Stimulation Test (LST).</p

Supplementary Data MS1 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV⁺ Men

Supplementary material 1: Rationale for intradermal administration of the vaccine, the use of pegylated interferon-alpha-2b (PegIntron) as adjuvant, immune assays.</p

Supplementary Data MS2 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV⁺ Men

Supplementary material 2: HPV-Typing of AIN lesions.</p